When biotech meets Bollywood ambition, you get Anthem — where every molecule dreams of becoming a blockbuster. Q2 FY26 was less about experiments in labs and more about experiments in scaling — Rs. 1,090 Cr revenue, 41% EBITDA margins, and enough new molecules to make the FDA blush. Management’s confidence? Sky-high. Their cash balance? Even higher. But can Rs. 993 Cr in cash and 14 commercial molecules guarantee a stable petri dish of profits? Keep reading — the real chemistry starts when we talk about Unit-IV’s Rs. 1,000 Cr expansion and that juicy GLP-1 play. 🧪
“Unit-IV will cost ₹1,000 Cr and double capacity in 2 years.” (Translation: Biotech’s version of a moonshot—literally and financially.*)
“Four new commercial molecules this half; total 14 now.” (Translation: Molecules are the new product SKUs.*)
“EBITDA margins sustainable at 36–37%.” (Translation: Unless the forex gods get grumpy.*)
“We’re building peptide and GLP-1 capabilities, fully integrated—no China fragments.” (Translation: Anthem wants to own your next Ozempic addiction. 💉*)